Extraskeletal (Soft-Tissue) Osteosarcoma Treatment
Current combined-modality therapy for extraskeletal osteosarcoma is managed similarly to skeletal osteosarcoma, with multimodal treatment outcomes appearing comparable to those for primary bone tumors. [1]
Core Treatment Components
Curative-intent therapy consists of complete surgical resection of the primary tumor with negative margins followed by systemic chemotherapy. [1]
Medication Selection Algorithm
Multi-agent systemic chemotherapy regimens used for osteosarcoma may include combinations of the following agents: [1]
- High-dose methotrexate, doxorubicin, cyclophosphamide, cisplatin, ifosfamide, etoposide, carboplatin. [1]
- Three active agents are preferred over two active agents for systemic chemotherapy (meta-analysis evidence). [1]
- High-dose methotrexate–containing three-drug regimens are superior to three-drug regimens without high-dose methotrexate (meta-analysis evidence). [1]
Preoperative (Induction) Versus Postoperative (Adjuvant) Chemotherapy
Most patients receive intravenous preoperative chemotherapy before definitive surgical resection. [1] Systemic chemotherapy may be started before or after definitive surgical resection of the primary tumor. [1]
Surgical Management
Complete resection of the primary tumor and any resectable metastatic disease confined to the lung after chemotherapy is associated with long-term survival potential. [1] Resection of the primary tumor with adequate margins is generally considered essential for cure. [1] Radiation therapy is used when surgery is not feasible or surgical margins are inadequate. [1]
Localized Versus Metastatic Disease Management
For localized disease, treatment options include surgical removal of the primary tumor, systemic chemotherapy (preoperative or postoperative), and radiation therapy if surgery is not feasible or margins are inadequate. [1] For patients with metastatic disease limited to lung lesions at diagnosis, treatment includes preoperative chemotherapy followed by resection of lung lesions when possible, followed by postoperative combination chemotherapy. [1]
Treatment Initiation Thresholds and Timing
Definitive lung surgery is generally performed after administration of preoperative chemotherapy. [1] After definitive surgical resection of the primary tumor, systemic chemotherapy is typically resumed before lung surgery to avoid delays in restarting chemotherapy. [1] Delays of more than 21 days until resumption of chemotherapy are associated with increased risk of adverse events and death in metastatic osteosarcoma surgical sequencing contexts. [1]
Prognostic and Response Considerations
After induction chemotherapy, pathologic tumor necrosis in the resected primary tumor is prognostic. [1] Patients with at least 90% necrosis in the primary tumor after induction chemotherapy have a better prognosis than patients with less necrosis. [1] Patients with less than 90% necrosis after initial chemotherapy have a higher rate of recurrence within the first 2 years than patients with necrosis of at least 90%. [1]
Common Pitfalls to Avoid
Chemo sequencing that causes delayed resumption of systemic therapy after primary tumor resection is a key risk factor. [1] Resumption delays of more than 21 days until restarting chemotherapy increase the risk of adverse events and death in metastatic osteosarcoma scenarios. [1]
Key Evidence Supporting the Approach
With current combined-modality therapy, extraskeletal osteosarcoma outcomes appear similar to outcomes for primary tumors of bone. [1] Event-free survival rates for patients with metastatic osteosarcoma at diagnosis are approximately 20% to 30% despite aggressive local control when metastatic disease is resectable after chemotherapy. [1] For patients with primary osteosarcoma and metastases limited to the lungs who achieve complete surgical remission, the 5-year event-free survival rate is approximately 20% to 25%. [1]